Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Aadi Bioscience Inc (AADI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aadi Bioscience's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.7500 +0.0700    +4.17%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.7494
-0.0006
-0.0343%
21:37:12 - Real-time Data
  • Volume: 147,778
  • Bid/Ask: 1.7000 / 1.9000
  • Day's Range: 1.6600 - 1.7600
Type:  Equity
Market:  United States
Aadi Bioscience 1.7500 +0.0700 +4.17%

Aadi Bioscience Company Profile

 
Read the Aadi Bioscience Inc company profile to learn more about the business and the management team. View Aadi Bioscience Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

88

Equity Type

ORD

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Contact Information

Address 17383 Sunset Boulevard Suite A250
Pacific Palisades, 90272
United States
Phone 424-744-8055
Fax -

Top Executives

Name Age Since Title
Pravin U. Dugel 57 2017 Independent Director
Michael T. Lotze 69 - Member of Scientific Advisory Board
Steven Prelack 64 2017 Independent Chairman
Peter A. Campochiaro - - Member of Scientific Advisory Board & Ophthalmology Advisory Board
Christopher D. Kontos - - Member of Scientific Advisory Board
Dietmar Vestweber - - Member of Scientific Advisory Board
Anupam Dalal 49 2011 Independent Director
Caley M. Castelein 50 2017 Independent Director
Cheryl L. Cohen 55 2018 Independent Director
David S. Boyer - - Member of Ophthalmology Advisory Board
Samir M. Parikh - - Member of Scientific Advisory Board
Peter K. Kaiser - - Member of Ophthalmology Advisory Board
Joseph H. Gardner 65 2011 Founder, President, Principal Executive Officer & Director
Jeffrey S. Heier 60 - Member of Ophthalmology Advisory Board
W. Daniel Stamer - - Member of Scientific Advisory Board
Emma Reeve 63 2021 Independent Director
Mohammad Hirmand 54 2023 Independent Director
Anupam Dalal 52 2021 Independent Director
Neil P. Desai 59 2011 Founder, Secretary & Executive Chairman
David J. Lennon 53 2023 President, CEO & Director
Richard Maroun 69 2017 Independent Director
Behzad Aghazadeh 53 2021 Independent Director
Karin M. Hehenberger 52 2021 Independent Director
Caley M. Castelein 53 2021 Independent Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AADI Price Commentary

Write your thoughts about Aadi Bioscience Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email